Anticancer agent 272

Anticancer agent 272 (Compound 2) is an anticancer agent. Anticancer agent 272 has significant anti-bladder cancer cell (T-24) activity (IC50: 2.81 μM) . Anticancer agent 272 consumes glutathione (GSH) through Fenton-like reaction, produces reactive oxygen species (ROS) and hydroxyl radicals (•OH), and induces apoptosis and ferroptosis. Anticancer agent 272 can enhance chemodynamic therapy (CDT) and promote tumor cell death through mitochondrial dysfunction and autophagy. Anticancer agent 272 has potential in the study of bladder cancer[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; Ferroptosis; Reactive Oxygen Species (ROS)

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Field of Research

Cancer

Smiles

BrC1=CN=C(N2[N]([Cu+2]34([Cl-][Cu+2]5([Cl-])([Cl-]4)[N](N6C7=NC=C(C=[N]75)Br)=C(C=C6C(C)C)C(C)C)[Cl-])=C(C=C2C(C)C)C(C)C)[N]3=C1

Molecular Formula

C26H34Br2Cl4Cu2N8

Molecular Weight

887.31

References & Citations

[1]Yang K, et al. Copper (II) Complexes of Pyrazolopyrimidine Derivatives as Anticancer Agents with Enhanced Chemodynamic Therapy through Bimodal Apoptosis and Ferroptosis. J Med Chem. 2025 Apr 10;68 (7) :7137-7152.